Similar articles

• Platelet transfusion therapy; the selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing.

  Yankee RA, Grumet FC, Rogentine GN. Yankee RA, et al. N Engl J Med. 1969 Nov 27;281(22):1208-12. doi: 10.1056/NEJM196911272812202. N Engl J Med. 1969. PMID: 5347838 No abstract available.
• The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets.

  Levy L, Woodfield DG. Levy L, et al. N Z Med J. 1984 Oct 24;97(766):719-21. N Z Med J. 1984. PMID: 6595558
• Selection of unrelated compatible platelet donors by lymphocyte HL-A matching.

  Yankee RA, Graff KS, Dowling R, Henderson ES. Yankee RA, et al. N Engl J Med. 1973 Apr 12;288(15):760-4. doi: 10.1056/NEJM197304122881504. N Engl J Med. 1973. PMID: 4688715 No abstract available.
• Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions.

  Sandler SG. Sandler SG. Haematologia (Budap). 1998;29(1):1-11. Haematologia (Budap). 1998. PMID: 9704252 Review.
• [Advances in platelet transfusion].

  Kummer H. Kummer H. Ther Umsch. 1973 Nov;30(11):797-801. Ther Umsch. 1973. PMID: 4585652 Review. German. No abstract available.